



**THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR
DISSEMINATION IN THE UNITED STATES**

XPHYTO THERAPEUTICS ANNOUNCES STOCK OPTION GRANTS

VANCOUVER, BRITISH COLUMBIA – August 8, 2019 – XPhyto Therapeutics Corp. (CSE: XPHY) (the “**Company**” or “**XPhyto**”), a science-focused cannabis company, announces that it has issued an aggregate of 2,500,000 stock options (the “**Options**”) in accordance with the Company’s stock option plan (the “**Option Plan**”) at an exercise price of \$1.25 per share. 700,000 Options will expire on August 7, 2020, 400,000 Options will expire on August 7, 2021 and 1,400,000 Options will expire on August 7, 2024. The Options were granted to certain consultants, directors and officers of the Company. 1,900,000 Options vest as of the date of the grant, and 600,000 Options will vest in stages with 20% vesting immediately, and the remainder to vest 20% every six months from date of grant. Pursuant to CSE policies, the Options and any Common Shares issued upon exercise will be subject to a four month and a day resale restriction from the date of grant.

The Option Plan allows the board of directors to issue the equivalent of up to 10% of the issued and outstanding share capital of the Company on a rolling basis.

ON BEHALF OF THE BOARD

"Hugh Rogers"
Director and CEO

About XPhyto Therapeutics Corp.

XPhyto is a science-focused cannabis company developing analytical testing, processing, and formulation capability in Canada and research, cultivation, extraction, import, distribution, and manufacturing in Germany. Two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified analytical testing capability, as well as extraction, isolation, and formulation facilities, and drug research and development expertise. XPhyto acquired 100% ownership of the German cannabis company Bunker Pflanzenextrakte GmbH, which has been granted a cannabis cultivation and extraction licence for scientific purposes by BfArM, the German Federal Institute for Drugs and Medical Devices.

For further information, please contact:

Hugh Rogers
CEO & Director
+1.780.818.6422
info@xphyto.com
www.xphyto.com

Robert Barth
VP European Corporate Development
+49 8331 99481 10
info@xphyto.com www.xphyto.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.